Objective To study the effect of Huang Kui capsule combined with valsartan on the level of serum cystein C (CysC) and oxidative stress with diabetic nephropathy.Methods Clinical data of 80 patients with diabetic nephropathy from department of endocrinology,Shijiazhuang City Fifth Hospital during Jan.and Dec.2014 were collected.According to different treatment method,the patients were divided into a control group and a test group,40 cases each.The control group was treated with valsartan dispersed tablets,0.5-1.0 g/d,one time per day,oral,1 month as a course of treatment,3 courses.The test group was given oral administration of Huang Kui capsule on the basis of the control group,1.5 g each time,3 times a day,1 month as a course of treatment,after 3 courses the efficacy was evaluated.Clinical curative effect,blood urea nitrogen (BUN),serum creatinine(Cr),urinary albumin excretion rate (UAER),CysC,malondialdehyde,superoxide dismutase(SOD),glutathione peroxidase(GSH-Px),blood sugar,and adverse reactions occurrence of the two groups were compared.Results The total efficacy of the test group was higher than that of the control group[92.5％ (37/40) vs 72.5 ％ (29/40)] (P ＜ 0.05).After treatment BUN,Cr,24 h UAER,Cys-C,malondialdehyde of the test group were lower than those of the control group [(5.21 ± 0.65) nmol/L vs (6.00 ± 0.72) nmol/L,(60.05 ± 7.60) μmol/L vs (64.21 ± 8.04) μmol /L,(98.07 ± 12.30) mg vs (125.20 ± 15.41) ag,(1.25 ±0.15) mg/L vs (2.83 ±0.34) mg/L,(3.22 ±0.38) nmol/L vs (4.50 ± 0.54) nmol/L(P ＜ 0.05)],SOD,GSH-Px of the test group were significantly higher than those of the control group[(93.11 ± 11.63) kU/L vs (86.54 ± 10.72) kU/L,(129.52 ± 16.09) kU/L vs (121.65 ±15.21) kU/L (P ＜0.05)].The glycemic index and incidence of adverse reactions had no significant differences between the two groups(P ＞ 0.05).Conclusion The effect of Huang Kui capsule combined with valsartan is better than valsartan alone,which can effectively regulate serum CysC and oxidative stress levels.%目的 探讨黄葵胶囊联合缬沙坦对糖尿病肾病患者血清胱抑素C(CysC)及氧化应激水平的影响.方法 收集2014年1-12月石家庄市第五医院内分泌科收治的80例糖尿病肾病患者临床资料,根据治疗方案不同分为试验组和对照组,各40例.对照组给予口服缬沙坦分散片治疗,0.5 ～1.0 g/d,每日1次,1个月为1个疗程,治疗3个疗程.试验组在对照组的基础上予以口服黄葵胶囊每次1.5g,每日3次,1个月为1个疗程,治疗3个疗程后评估疗效.比较两组临床疗效,血尿素氮(BUN)、血肌酐(Cr)、尿白蛋白排泄率(UAER)、Cys-C、丙二醛(MDA)、超氧化物歧化醇(SOD)、谷胱甘肽过氧化物酶(GSH--Px)、血糖变化情况,及不良反应发生情况.结果 研究组患者总有效率高于对照组[92.5％ (37/40)比72.5％ (29/40)] (P ＜0.05);治疗后,试验组血清BUN、Cr、24hUAER、CysC、丙二醛低于对照组[(5.21±0.65) nmol/L比(6.00±0.72) nmol/L、(60.05±7.60)μmol/L比(64.21±8.04) μmol/L、(98.07±12.30) mg比(125.20±15.41) mg、(1.25±0.15) mg/L比(2.83±0.34) mg/L、(3.22±0.38) nmol/L比(4.50±0.54) nmol/L],研究组SOD、GSH-Px高于对照组[(93.11±11.63) kU/L比(86.54±10.72) kU/L、(129.52±16.09) kU/L比(121.65±15.21) kU/L] (P＜0.05).两组血糖指标及不良反应发生率比较差异无统计学意义(P＞0.05).结论 黄葵胶囊联合缬沙坦对糖尿病肾病患者效果优于单用缬沙坦,能够有效调节血清Cys-cC及氧化应激水平.
展开▼
